TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05190471: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Sponsor: Bio-Path Holdings, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,864,168

Rescue Site Savings

+$2,544,696

Unlock Full NCT05190471 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05190471 Rescue Dossier →